A5069186200- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Atrial Fibrillation Management and Outcomes
- Acute Myocardial Infarction Research
- CNS Lymphoma Diagnosis and Treatment
- Venous Thromboembolism Diagnosis and Management
Princess Alexandra Hospital
2023-2024
St Vincent's Hospital
2021
Abstract Polatuzumab vedotin (Pola) is an approved therapy in combination with rituximab and bendamustine for relapsed or refractory diffuse large B‐cell lymphoma (RR‐DLBCL) based on positive results of the landmark phase II randomised G029365 trial. However, trial many novel therapies RR‐DLBCL have not been replicated routine care cohorts, as patient populations are heterogeneous eligibility increasingly restrictive. We evaluated outcomes from pola ± patients enrolled a compassionate access...
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: RRDLBCL outcomes remain poor despite autologous transplant and CAR-T therapies offering potential cure to a minority. Evidence for current is mostly from phase II trials with stringent eligibility criteria. Applicability real-world populations poorly understood. PolaBR efficacy in RR DLBCL was shown the landmark GO29365 study (BCT02600897; Sehn Blood Adv 2022). However, of routine care patients (pts) who fail meet original...
Direct acting oral anticoagulants (DOAC) are now commonly prescribed medications. Urgent reversal of their anticoagulant effect is sometimes required in emergency situations. In Australia, a specific agent for factor Xa (FXa)-inhibitor DOAC not available. Instead, two non-specific haemostatic agents, activated prothrombin complex concentrate (aPCC) and 3 factor-prothrombin (3F-PCC), used off-label despite paucity evidence effectiveness or safety.To provide further insight into the efficacy...